Co-Diagnostics Inc SEC Filings

Orca Capital AG reported beneficial ownership of 4,809,500 shares of Co-Diagnostics, Inc. (CODX), representing 9.9% of the company's common stock. The filing states Orca Capital has sole voting and dispositive power over all 4,809,500 shares and that the percentage is calculated using an outstanding share count of 48,142,582 after a registered offering noted in the issuer's prospectus.

The statement is submitted on a Schedule 13G format and includes a certification that the holdings were not acquired to change or influence control of the issuer.

Co-Diagnostics, Inc. (CODX) filed a prospectus supplement that discloses an offering structure and company capitalization details. The document shows placement agent fees of $269,332 and gross proceeds to the company (before expenses) of $3,578,268 for the offering line items shown. As of June 30, 2025, the company had 41,031,146 shares issued and 36,182,468 shares outstanding. The filing also discloses outstanding equity-based instruments including 970,570 options (weighted-average exercise $2.26), 1,902,531 restricted stock units, 465,000 warrants (weighted-average exercise $9.13), and 9,937,236 additional shares reserved for future issuance under equity incentive plans. The prospectus references prior SEC filings incorporated by reference and describes how offering proceeds and share counts are presented on actual, pro forma (including 2,341,114 ATM Sales for $663,728), and as-adjusted bases (giving effect to issuance of 9,619,000 shares at $0.40 per share after fees).

Co-Diagnostics insider Richard David Abbott received 220,000 restricted stock units (RSUs) on 08/13/2025 under the Issuer's 2015 Long Term Incentive Plan. Each RSU represents the contingent right to receive one share of common stock upon vesting. After the grant Abbott beneficially owns 350,438 shares of common stock, with the 220,000 RSUs vesting in six installments beginning 11/23/2025 and continuing every six months thereafter. The Form 4 was signed 08/15/2025 and lists Abbott as President and a director.

Co‑Diagnostics, Inc. reported an insider award to Brian L. Brown, the company's Chief Financial Officer. On 08/13/2025 Mr. Brown was granted 225,000 restricted stock units (RSUs) under the issuer's 2015 Long Term Incentive Plan, as amended; each RSU represents the contingent right to receive one share of common stock upon vesting. The RSUs vest in six installments beginning 11/23/2025 and then every six months thereafter. Following the grant, the filing shows Mr. Brown beneficially owns 471,667 shares of common stock in total. The RSUs carry a reported price of $0.00, consistent with restricted units rather than an option.

Co-Diagnostics, Inc. (CODX) insider report: Dwight H. Egan, listed as Director and Chief Executive Officer, was granted 275,000 restricted stock units (RSUs) on 08/13/2025 under the Issuer's 2015 Long Term Incentive Plan, as amended. Each RSU represents the contingent right to receive one share of common stock upon vesting. Following the grant, Mr. Egan beneficially owns 575,833 shares of common stock. The RSUs vest in six equal installments beginning 11/23/2025 and continue every six months thereafter.

Co-Diagnostics insider grant and holdings summary: Director Eugene Durenard was granted 125,000 restricted stock units (RSUs) on 08/13/2025 under the Issuer's 2015 Long Term Incentive Plan. Each RSU represents the contingent right to one share of common stock upon vesting. The RSUs carry a $0.00 price and vest in six installments beginning 11/23/2025 and every six months thereafter. Following the reported transaction the filing shows 228,333 shares beneficially owned, with 103,333 common shares indicated as underlying currently reportable holdings. The Form 4 was filed by one reporting person and signed 08/15/2025.

James B. Nelson, a director of Co-Diagnostics, Inc. (CODX), was granted 125,000 restricted stock units (RSUs) on 08/13/2025. Each RSU converts to one share of common stock upon vesting, and the award shows 103,333 underlying shares currently attributable, producing 228,333 shares beneficially owned after the grant. The RSUs carry a $0.00 price and vest in six equal installments beginning 11/23/2025 and continuing every six months thereafter. The grant was reported on a Form 4 filed by the reporting person as an individual.